SLCO1B1 and Myalgia: Among drug–gene pairs relevant for the cholesterol-lowering drug cohort, for simvastatin-SLCO1B1, a risk of ADRs such as muscle problems including myalgias and rhabdomyolysis was reported in previous studies for the poor metabolism/function phenotype [42, 43].